Stock Information
symbol line chart

KIDSOrthoPediatrics corp

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

David R. Bailey

Location

Indiana, USA

Exchange

Nasdaq

Website

https://orthopediatrics.com

Summary

OrthoPediatrics Corp.

Company Info

CEO

David R. Bailey

Location

Indiana, USA

Exchange

Nasdaq

Website

https://orthopediatrics.com

Summary

OrthoPediatrics Corp.

AI Insights for KIDS
2 min read

Quick Summary

OrthoPediatrics Corp. is a medical device company focused on implants and instruments for children with orthopedic conditions. The company designs, develops, markets, and sells anatomically appropriate products for pediatric trauma, deformity correction, scoliosis, sports medicine, and other orthopedic procedures. Its main customers are pediatric orthopedic surgeons, children’s hospitals, ambulatory surgery centers, and healthcare systems that treat infants, children, and adolescents. The company operates in the United States and internationally, with a specialized focus that differentiates it from broader adult-oriented orthopedic implant companies. Based on the provided fundamentals, OrthoPediatrics generated about $70.5 million in operating revenue and remains unprofitable, with negative EPS and negative net income.

The Bull Case

  • OrthoPediatrics’ biggest strength is its focused position in pediatric orthopedic implants and devices.
  • This specialization gives the company a clearer identity than broader orthopedic competitors and allows it to design products around the specific needs of children.
  • Pediatric orthopedic surgery requires attention to growth plates, smaller anatomy, deformity correction, and age-appropriate instrumentation, which can create a defensible niche.
  • The company also has a strong gross profit base relative to revenue, suggesting that its products may carry attractive device-level margins before operating expenses.
  • Its sentiment rating is high in the provided data, which may indicate favorable market perception or investor interest despite current losses.

The Bear Case

  • The company’s main weakness is that it remains unprofitable, with negative EPS, negative operating income, and negative net income.
  • Negative earnings make valuation more difficult and can reduce investor patience if revenue growth slows.
  • The company’s employee base and market capitalization suggest it is much smaller than many of its orthopedic competitors, which may limit sales reach, research spending, and contracting power.
  • Its EV-to-operating-cash-flow figure appears high, which may signal that cash generation is limited relative to enterprise value.
  • The company is also concentrated in a specialized market, so any slowdown in pediatric orthopedic procedure demand or competitive displacement could have an outsized impact.

Key Risks

  • A key risk is continued unprofitability, which could pressure the balance sheet, investor confidence, and valuation if losses persist.
  • The company faces competition from much larger orthopedic and spine companies with greater resources, broader product portfolios, and stronger hospital contracting power.
  • Regulatory requirements, product liability exposure, and clinical performance issues are important risks for any implantable medical device company.
  • Healthcare reimbursement pressure and hospital budget constraints could also limit adoption or pricing flexibility.

What to Watch

UpcomingFor the most recent reported period, the provided data points to Q3 2026 fundamentals rather than a detailed narrative of specific corporate events.
UpcomingThe company generated about $70.5 million in total revenue and about $52.4 million in gross profit, indicating that its product portfolio continued to produce meaningful sales despite continued losses.
UpcomingOperating income was negative at roughly -$4.07 million, and net income was negative at roughly -$7.16 million, showing that profitability remains a key issue.
ExpectedNext quarter performance will likely depend on procedure volumes, surgeon adoption, product availability, and the company’s ability to control operating expenses.

Price Drivers

  • The stock price is likely driven primarily by revenue growth, gross margin performance, path to profitability, and investor confidence in the pediatric orthopedic device market.
  • The company reported negative EPS of -0.30 and net income of about -$7.16 million, so investors may focus heavily on whether operating losses narrow over time.
  • Valuation also matters because the company trades at an EV-to-revenue ratio of about 2.56 and a price-to-book ratio of about 1.73, while traditional earnings multiples are not meaningful due to losses.
  • Trading activity, market sentiment toward small and mid-cap medical device companies, and hospital procedure volumes can also influence the share price.

Recent News

  • The provided recent news feed does not appear to contain clear company-specific news about OrthoPediatrics Corp.
  • Several articles mention children, kids’ products, media content, consumer brands, or other companies, but they do not directly describe OrthoPediatrics’ operations, partnerships, controversies, earnings releases, or acquisitions.
  • Therefore, no reliable recent company-specific development can be concluded from the supplied news items.
  • Based on the fundamentals, the most relevant recent information is the Q3 2026 financial profile showing revenue of about $70.5 million and continued net losses.

Market Trends

  • OrthoPediatrics is affected by broader medical device trends, including hospital procedure volumes, reimbursement policies, supply chain conditions, and demand for specialized surgical technologies.
  • Pediatric orthopedic care is a niche within orthopedics, but it benefits from long-term demand for trauma repair, deformity correction, scoliosis treatment, and sports injury procedures.
  • The market also favors companies that can provide procedure-specific systems, surgeon training, and reliable instrument logistics.
  • At the same time, healthcare systems continue to pressure vendors on pricing, contracting, and evidence of clinical value.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on KIDS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show